Marco-Antonio Montes-Cano



Background: Different factors may influence the ability to clear the virus C hepatitis. Viral and host factors contribute to success or failure of antiviral therapy. The aim of this stud was to analyze the combined effect of interleukin-28B polymorphism of recipient and donor in the response to the treatment on a cohort of patients undergoing liver transplant.

Methods: A total of 69 patients were included in the study. Genotyping of rs12979860 was performed using a TaqMan allelic discrimination assay.

Results: The end treatment response in CC/CC group was 73.3%, being the 80.6% in the second group of patients (CC/non-CC or non-CC/CC). The lowest rate of response (40.0%) was found in the group with both genotypes non-CC/non-CC. Therefore, we grouped as good responders (CC/CC and CC/non-CC or non-CC/CC) and were compared with the non-CC/non-CC group (p= 0.005, CI 95%, OR: 5.4 [1.22-22.9]). The same analysis was performed in respect to sustained virological response (p= 0.08, OR: 2.81 CI 95% [0.73-11.06]).

Conclusion: The response to antiviral therapy in liver transplant patients is associated to IL28B genotype and it appears sufficient the presence of a CC IL-28B genotype at one member of the pair receptor/donor to achieve adequate rates of response.


Hepatitis C virus, IL-28B, interferon alpha-2a, liver transplant, polymorphism



Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398.

Berg T. Tailored treatement for hepatitis C. Clin Liver Dis 2008; 12: 5007-528.

Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatement-induced viral clearance. Nature 2009; 461: 399-401.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.

Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T et al. Variants in IL28B in liver recipients and donors correlate with response to peginterferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.

Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy befote and after liver transplantation. Am J Transplant 2011; 11: 1051-1057.

EASL Recommendations on Treatment of Hepatitis C 2015.

Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol 1991; 13: 372-373.

Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J. Hepatol 2003; 39: 389-396.

Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J. Hepatol 2009; 50: 719-728.

Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132: 1746-1756.

Lazaruk K, Walsh PS, Oaks F, Gilbert D, Rosenblum BB, Menchen S et al. Genotyping of forensic short tandem repeat (STR) systems based on sizing precision in a capillary electrophoresis instrument. Electrophoresis 1998; 19: 86-93.

Coto-Llerena M, Crespo G, González P, Koutsoudakis G, Miquel R, Navasa M, et al. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol. 2012; 56: 355-8.

Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011; 53: 317-24.

Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R et al. CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int. 2013; 33: 72-78.

Duarte-Rojo A(1), Budhraja V, Veldt BJ, Goldstein DD, Watt KD, Heimbach JK et al. Interleukin-28B and fribrosing cholestatic hepatitis in posttrasplant hepatitis C: a case-control study and literatur review. Liver Tranpl. 2013; 19: 1311-1317.

Ackefors M, Nyström J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation –influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepat. 2013; 20: 770-778.

Lin FC, Young HA. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014; 25: 369-376.

Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, et al. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol 2011 July 27; 3: 198-204.

Zhang L, Lu Q, Yang Z, Wang X, Cai L, Liu X, et al. Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: A meta-analysis. Human Immunology. 2014; 75: 1268–1275.

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.